A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Recruiting

Phase 1

Delandistrogene MoxeparvovecA Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Sponsor:

Sarepta Therapeutics, Inc.

Code:

NCT06597656

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 4 - 8

Healthy Volunteers: Not accepted

Interventions

delandistrogene moxeparvovec

Plasmapheresis

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-11. This information was provided to ClinicalTrials.gov by Sarepta Therapeutics, Inc. on 2025-03-03.